Pfizer Stock Can Sink More. Here Is How

Core Insights - Pfizer is facing significant challenges, including a cautious outlook for 2026 and a substantial patent cliff, which may lead to a decline in stock value [3][9] Group 1: Financial Performance and Outlook - Pfizer's shares have recently fallen after a year of modest growth, with future profits expected to be below analyst forecasts due to ongoing challenges [3] - The company is projected to lose $17-$18 billion in annual revenues by 2028 due to expiring patents on key medications [9] - Expected sales for COVID-19 products in 2026 are projected to decrease to $5 billion, a $1.5 billion drop from 2025 estimates, significantly impacting profit outlook [9] Group 2: Risks and Market Behavior - Historical data shows that Pfizer's stock has experienced significant declines during market downturns, including a 39% drop during the Dot-Com Bubble and a 53% drop during the Global Financial Crisis [5] - The company has faced declines of 24% and 29% during the 2018 correction and the COVID-19 pandemic, respectively, indicating vulnerability to market fluctuations [5] Group 3: Pipeline and Innovation Challenges - Pfizer's pipeline execution faces risks due to setbacks, including the discontinuation of the GLP-1R agonist danuglipron and halting of two Seagen pipeline assets [9] - The company aims to develop eight or more oncology blockbusters by 2030, but current challenges may hinder this goal [9]